ReWalk intends to use the net proceeds from the offering for sales, marketing, market development activities, broadening third-party payor coverage, and R&D costs for its lightweight “soft suit” exoskeleton technology for various lower limb disabilities, including stroke and other indications affecting the ability to walk.